Varda Space Industries · 1 day ago
Scientist, Drug Substance Development
Varda is a company focused on developing commercial space infrastructure, including pharmaceutical processing in low Earth orbit. The Scientist in Drug Substance Development will lead efforts to improve therapeutics in microgravity, overseeing pharmaceutical development projects and collaborating with engineers and scientists.
AerospaceManufacturingProduct Design
Responsibilities
Serve as technical lead for pharmaceutical development projects
The candidate will be responsible for supporting drug substance development including characterization of materials, crystallization screening and early-stage process characterization
Responsibilities include design, planning, and hands-on execution of laboratory studies
Drug substance characterization spans solid-state, physicochemical, and particle analysis
Collaborate with process engineers and analytical development scientists
Qualification
Required
Ph.D. in materials science, chemical engineering, organic chemistry, biochemistry or related fields or M.S. degree in related field with 3+ years of industry experience
Preferred
Ph.D. degree in relevant field with 3+ years of industry experience
Experienced in drug substance development of small molecules (solvent screen, form screening and selection, stability studies)
Experience with cradle-to-crave development from early R&D through commercialization
Benefits
Exciting team of professionals at the top of their field working by your side
Equity in a fully funded space startup with potential for significant growth (interns excluded)
401(k) matching (interns excluded)
Unlimited PTO (interns excluded)
Health insurance, including Vision and Dental
Lunch and snacks provided on site every day. Dinners provided twice a week.
Maternity / Paternity leave (interns excluded)
Company
Varda Space Industries
Low Earth orbit is open for business.
Funding
Current Stage
Growth StageTotal Funding
$328.02MKey Investors
Alumni VenturesCaffeinated CapitalKhosla Ventures
2025-07-10Series C· $187M
2024-12-19Series C
2024-04-05Series B· $90M
Recent News
Business Insider
2025-12-25
2025-12-17
Company data provided by crunchbase